NCT07270666Recruiting
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
Pragmatic Pilot Study of ctDNA Informed Immune Checkpoint Inhibitor De-escalation in Advanced/Recurrent Mismatch Repair Deficient (MMR-D)/Microsatellite Instability High (MSI-H) Endometrial Cancer Using Standard of Care Treatments
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair deficient (MMR-D) gene or microsatellite instability high (MSI-H) gene. The researchers will see how doctors and their patients use the results of ctDNA testing after 1 year of standard chemotherapy and immune checkpoint inhibitor (ICI) treatment to decide whether to continue maintenance ICI treatment past 1 year. The researchers will also look at the health outcomes of people in this study (for example, whether they are cancer free at the end of their participation in the study).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 26 Nov 2025
- Start date
- 25 Nov 2025
- Primary completion date
- Nov 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Endometrial cancer
- NCT number
- NCT07270666
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 25 Nov 2025 to the primary completion date, Nov 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients must have pathologically confirmed endometrial cancer
- Patients with advanced endometrial cancer
- Stage III with residual disease
- °Select patients with Stage III disease and no residual disease can be enrolled after discussion with PI
- Stage IV
- Recurrent endometrial cancer after adjuvant therapy only
- Patients can have primary or planned interval surgery
- MMR-D on immunohistochemistry OR MSI-H using any commercially available test
- Patients with treated brain metastases are eligible if follow up brain imaging after CNS directed therapy shows no evidence of progression.
- Eligible for standard of care chemotherapy with immune checkpoint inhibitor per treating investigator with no clinical contraindications
- For the up to 10 patients who are allowed to enroll after C1D1 of standard of care treatments, they need to be on treatment with no clinical evidence of disease progression.
- Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy.
- Patients may have received prior hormonal therapy for treatment of endometrial cancer.
- Patients may not have received prior therapy with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapeutic antibody or other similar agents.
- Except for the up to 10 patients who are allowed to enroll after C1D1 of standard of care treatments (chemotherapy and/or immune checkpoint inhibitors) per protocol.
- Age ≥ 18
- Not Pregnant and Not Nursing
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (All Protocol Activites) Coordinator of this site? Confirm its status | Basking Ridge | United States | Recruiting |
| Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) Coordinator of this site? Confirm its status | Commack | United States | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) Coordinator of this site? Confirm its status | Harrison | United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) Coordinator of this site? Confirm its status | Middletown | United States | Recruiting |
| Memorial Sloan Kettering Bergen (All Protocol Activities) Coordinator of this site? Confirm its status | Montvale | United States | Recruiting |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Memorial Sloan Kettering Nassau (All Protocol Activities) Coordinator of this site? Confirm its status | Rockville Centre | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.